• PDF / 170,383 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 36 Downloads / 161 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 3 case reports In a report, three men aged 62-71 years were described, who developed mild skin injury, fever, myelosuppression, leucopenia or moderate gastrointestinal response following treatment with iodine-125, nivolumab or pembrolizumab for lung squamous cell carcinoma or lung adenocarcinoma [routes and times to reaction onsets not stated]. Patient 1: A 62-year-old man developed mild skin injury and fever following treatment with iodine-125 and nivolumab for lung squamous cell carcinoma. The man, who had stage IIIA right-lung squamous cell carcinoma, developed right supraclavicular lymph node metastasis. Subsequently, he was treated with iodine-125 seed brachytherapy. Brachytherapy was performed under local anaesthesia with lidocaine. He received implants of the iodine-125 radioactive particles 125Gy through percutaneous puncture. Thereafter, partial response was noted. Two months after the brachytherapy, he started receiving nivolumab 100mg for 10 months. Complete response was observed. However, he developed mild skin injury and fever, which were considered to be secondary to iodine-125 and nivolumab therapy. He promptly received unspecified therapy, leading to resolution of skin injury and fever. Patient 2: A 64-year-old man developed myelosuppression and leucopenia following treatment with iodine-125 and pembrolizumab for lung adenocarcinoma. The man, who had stage IV lung adenocarcinoma, developed metastasis of the retroperitoneal lymph node. Subsequently, he was treated with iodine-125 seed brachytherapy. Brachytherapy was performed under local anaesthesia with lidocaine. He received implants of the iodine-125 radioactive particles 125Gy through percutaneous puncture. Thereafter, stable disease was noted. Two months after the brachytherapy, he started receiving pembrolizumab 200mg for 6 months. Complete response was observed. However, he developed myelosuppression and leucopenia, which were considered to be secondary to iodine-125 and pembrolizumab therapy. He promptly received unspecified therapy, leading to resolution of myelosuppression and leucopenia. Patient 3: A 71-year-old man developed moderate gastrointestinal response following treatment with iodine-125 and pembrolizumab for lung squamous cell carcinoma. The man, who had stage III C lung squamous cell carcinoma, developed a tumour in upper lobe of the right lung. Subsequently, he was treated with iodine-125 seed brachytherapy. Brachytherapy was performed under local anaesthesia with lidocaine. He received implants of the iodine-125 radioactive particles 82Gy through percutaneous puncture.Thereafter, stable disease was noted. Two months after the brachytherapy, he started receiving pembrolizumab 200mg for 6 months. Partial response was observed. However, he developed moderate gastrointestinal response, which was considered to be secondary to iodine-125 and pembrolizumab therapy. He promptly received unspecified therapy, leading to resolution of moderate gastrointestinal response. Sui A, et al. Clinical Application of Iodin